Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q1

9776.TEDINET S100RLX2
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥4.9bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥20.1bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥4.9bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥76m2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥132m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥81m2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥1.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥223m2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥74m2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥222m2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥6m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥569m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥78m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥9m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥125m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥16.7bnat 2023-06-30Cons.Assets
Total assets¥16.5bnat 2023-03-31Cons.Assets
Total assets¥16.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥5.9bnat 2023-06-30Cons.Liabilities
Total liabilities¥5.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥10.8bnat 2023-06-30Cons.Net assets
Net assets / equity¥10.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥10.4bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.8bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥3.7bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥1.722023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥170.532022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥23.352022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio63.2%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio64.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥18m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥18m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥855,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥12m
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥62m
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥108m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥431m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥265m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥166m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥4m
—segment totalrevenue2023-04-01 → 2023-06-30¥5.1bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥4.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥166m
—segment totalsegment profit2023-04-01 → 2023-06-30¥166m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥4.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥167m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥178m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥23m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥22m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥846,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥15m
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥200m
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥78m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥376m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥233m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥143m
jpcrp040300-q1r_E04950-000Medical Devices Sales And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥3m
—segment totalrevenue2022-04-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥4.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥143m
—segment totalsegment profit2022-04-01 → 2022-06-30¥275m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥5.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥4.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥144m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥290m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 376
ItemContextValueUnit
Other nclPrior1YearInstant20483000JPY
Other nclCurrentQuarterInstant63953000JPY
Noncurrent liabilitiesPrior1YearInstant2383779000JPY
Noncurrent liabilitiesCurrentQuarterInstant2352852000JPY
LiabilitiesPrior1YearInstant5640294000JPY
LiabilitiesCurrentQuarterInstant5868322000JPY
Capital stockPrior1YearInstant983350000JPY
Capital stockCurrentQuarterInstant983350000JPY
Capital surplusPrior1YearInstant1015270000JPY
Capital surplusCurrentQuarterInstant1015270000JPY
Retained earningsPrior1YearInstant9304184000JPY
Retained earningsCurrentQuarterInstant9233592000JPY
Treasury stockPrior1YearInstant-757451000JPY
Treasury stockCurrentQuarterInstant-757451000JPY
Shareholders equityPrior1YearInstant10545353000JPY
Shareholders equityCurrentQuarterInstant10474760000JPY
Valuation difference on available for sale securitiesPrior1YearInstant40044000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant46554000JPY
Valuation and translation adjustmentsPrior1YearInstant40044000JPY
Valuation and translation adjustmentsCurrentQuarterInstant46554000JPY
Non controlling interestsPrior1YearInstant295588000JPY
Non controlling interestsCurrentQuarterInstant267072000JPY
Net assetsPrior1YearInstant10880986000JPY
Net assetsCurrentQuarterInstant10788388000JPY
Liabilities and net assetsPrior1YearInstant16521281000JPY
Liabilities and net assetsCurrentQuarterInstant16656710000JPY
Net salesPrior1YTDDuration4900050000JPY
Net salesCurrentYTDDuration4922593000JPY
Cost of salesPrior1YTDDuration3428989000JPY
Cost of salesCurrentYTDDuration3523470000JPY
Gross profitPrior1YTDDuration1471061000JPY
Gross profitCurrentYTDDuration1399123000JPY
Selling general and administrative expensesPrior1YTDDuration1339384000JPY
Selling general and administrative expensesCurrentYTDDuration1323455000JPY
Operating incomePrior1YTDDuration131676000JPY
Operating incomeCurrentYTDDuration75668000JPY
Interest income noiPrior1YTDDuration29000JPY
Interest income noiCurrentYTDDuration16000JPY
Dividends income noiPrior1YTDDuration2817000JPY
Dividends income noiCurrentYTDDuration2803000JPY
Rent income noiPrior1YTDDuration11262000JPY
Rent income noiCurrentYTDDuration9765000JPY
Subsidy income noi bountyPrior1YTDDuration87229000JPY
Subsidy income noi bountyCurrentYTDDuration0JPY
Other noiPrior1YTDDuration4123000JPY
Other noiCurrentYTDDuration4552000JPY
Non operating incomePrior1YTDDuration105462000JPY
Non operating incomeCurrentYTDDuration17139000JPY
Interest expenses noePrior1YTDDuration2031000JPY
Interest expenses noeCurrentYTDDuration1821000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass